Please select the option that best describes you:

Would you consider reserving CDK4/6 Inhibitors as second line treatment in patients with advanced HR+ HER2 negative breast cancer given SONIA and PALMIRA trial results?  



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice